BridgeBio Pharma (BBIO) Current Deferred Revenue (2019 - 2026)

BridgeBio Pharma (BBIO) has 6 years of Current Deferred Revenue data on file, last reported at $6.1 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue fell 47.38% year-over-year to $6.1 million; the trailing twelve-month figure through Mar 2026 stood at $6.1 million (down 47.38% YoY), and the FY2025 full-year result was $7.2 million, up 1697.5% from the prior year.
• Current Deferred Revenue slipped to $6.1 million in Q1 2026, from $7.2 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $100.0 million in Q2 2024 to a low of $400000.0 in Q4 2024.
• A 5-year average of $19.6 million and a median of $8.3 million in 2022 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue sank 93.44% in 2024 and jumped 1697.5% in 2025, its largest moves.
• Tracing BBIO's Current Deferred Revenue over 5 years: stood at $19.8 million in 2022, then plunged by 69.21% to $6.1 million in 2023, then slumped by 93.44% to $400000.0 in 2024, then jumped by 1697.5% to $7.2 million in 2025, then decreased by 14.95% to $6.1 million in 2026.
• Business Quant data shows BBIO's Current Deferred Revenue at $6.1 million in Q1 2026, $7.2 million in Q4 2025, and $9.1 million in Q3 2025.